

Subject: Specialised Services Circular (SSC 2523)
Sent on behalf of: Chair of the SW Specialised Service Circular Group

Dear Colleagues,

Please find attached the following Specialised Services Circular(s):

SSC Number	SSC Title	Trusts approved to prescribe in accordance with the SSC, providing appropriate internal governance arrangements are in place
SSC 2523	Clinical Commissioning Policy 2201 Ranibizumab in Retinopathy of Prematurity (ROP)	University Hospitals Bristol & Weston NHS Foundation Trust

Is an implementation plan required from all SW trusts (regardless of commissioned status) for this SSC? **No**

For all other South West region trusts this is for information only.

Trusts should ensure that use is registered on the Blueteq system (if appropriate).

Treatment will only be funded where the drugs minimum dataset is fully and accurately populated.

Please direct any queries to: england.speccomm-southwest@nhs.net

Specialised Commissioning South West
NHS England
360 Bristol
Marlborough Street
Bristol
BS1 3NX
Email: england.speccomm-southwest@nhs.net

02 June 2023

All Chief Executives

All Medical Directors

All Chief Pharmacists

Dear Colleagues,

Clinical Commissioning Policy 2201 Ranibizumab in Retinopathy of Prematurity (ROP)

This letter is to inform you that NHS England has reviewed the evidence for the use of **Ranibizumab in Retinopathy of Prematurity (ROP)** and we have concluded that there is sufficient evidence to make this available to babies who fulfil the criteria within the published policy.

Ranibizumab will be commissioned and funded by NHS England, from April 2023, under existing contractual arrangements with providers who are commissioned for the provision of neonatal intensive care (NICU) and specialised ophthalmology services. This will ensure that patients have access to the full range of treatment options and clinical expertise, thus ensuring the optimal procedure is used. The decision to use **Ranibizumab in Retinopathy of Prematurity (ROP)**, must be made by the treating clinician and wider MDT in conjunction with the babies' family.

In addition:

- Trusts must ensure that only invoices for the drug procurement costs of Ranibizumab in this indication are invoiced to NHS England and that they are also submitting complete and accurate information via the drugs minimum dataset (MDS). All other on cost are in block arrangements.
- In line with the terms and conditions included in the NHS Standard Contract and as per Schedule 6a Reporting Requirements for drugs will apply. Payment of Trust invoices will be contingent on the completion of the MDS record and this information being made available in a timely way.
- Patients must be registered via Blueteq and meet the clinical criteria on the registration form.
- Payment of Trust invoices will be contingent on Blueteq registration and the full drugs MDS record applicable to the drug being completed and this information being made available in a timely way.
- Trusts must ensure that local governance aspects (e.g. technical issues, education & training, patient information) have been identified and addressed

for all staff groups (as appropriate) in order to permit the safe delivery of this treatment.

The published policy can be found here:

<https://www.england.nhs.uk/publication/ranibizumab-in-retinopathy-of-prematurity/>

I would be grateful if this letter could be circulated to relevant clinical and contracting teams to aid awareness and implementation.

With best wishes,



Vinay Takwale (VT)
Medical Director NHS England South West
Region & Consultant Orthopaedic Surgeon



Tracey Williams
Principal Pharmacist